2024-520385-57-01RecruitingPhase 1
A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jun 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (estimated)
- First submitted
- 28 Jul 2025
- Start date
- 26 Nov 2025
- Lead sponsor
- Climb Bio Inc.
- Diseases
- Lupus (SLE)
- EU CT number
- 2024-520385-57-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 11
- 8 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Multiprofile Hospital For Active Treatment Saint Georgi EAD | Plovdiv | Bulgaria | Recruiting |
| Multispecialty hospital for active treatment Sveta Sofia EOOD | Sofiya | Bulgaria | Recruiting |
| Complexo Hospitalario Universitario A Coruña | A Coruña | Spain | Recruiting |
| Parc Tauli Hospital Universitari | Sabadell | Spain | Recruiting |
| Laiko General Hospital of Athens | Athens | Greece | Recruiting |
| Ippokratio General Hospital of Thessaloniki | Thessaloniki | Greece | Recruiting |
| Geniko Nosokomeio Thessalonikis George Papanikolaou | Thessaloniki | Greece | Recruiting |
| Spitalul Clinic Judetean De Urgenta Cluj | Cluj-Napoca | Romania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.